Galectin Therapeutics Inc (NASDAQ: GALT) kicked off on Monday, down -4.20% from the previous trading day, before settling in for the closing price of $4.05. Over the past 52 weeks, GALT has traded in a range of $1.07-$7.13.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -23.89%. While this was happening, its average annual earnings per share was recorded 35.53%. With a float of $45.57 million, this company’s outstanding shares have now reached $64.47 million.
Galectin Therapeutics Inc (GALT) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Galectin Therapeutics Inc is 29.33%, while institutional ownership is 15.97%. The most recent insider transaction that took place on Dec 31 ’25, was worth 33,089. In this transaction Chief Medical Officer of this company sold 8,125 shares at a rate of $4.07, taking the stock ownership to the 0 shares. Before that another transaction happened on Jan 02 ’26, when Company’s Officer proposed sale 84,000 for $4.20, making the entire transaction worth $352,800.
Galectin Therapeutics Inc (GALT) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.19 earnings per share (EPS), lower than consensus estimate (set at -0.16) by -0.03.
According to the Wall Street analysts, stocks earnings will be around 35.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.03% during the next five years compared to -23.89% drop over the previous five years of trading.
Galectin Therapeutics Inc (NASDAQ: GALT) Trading Performance Indicators
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.59, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of Galectin Therapeutics Inc (GALT)
Compared to the last year’s volume of 0.57 million, its volume of 0.44 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 32.60%.
During the past 100 days, Galectin Therapeutics Inc’s (GALT) raw stochastic average was set at 10.47%, which indicates a significant increase from 9.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.47 in the past 14 days, which was higher than the 0.42 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.36, while its 200-day Moving Average is $3.46. Nevertheless, the first resistance level for the watch stands at $4.10 in the near term. At $4.32, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.46. If the price goes on to break the first support level at $3.73, it is likely to go to the next support level at $3.59. Now, if the price goes above the second support level, the third support stands at $3.37.
Galectin Therapeutics Inc (NASDAQ: GALT) Key Stats
The company with the Market Capitalisation of 250.18 million has total of 64,473K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -47,050 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -8,180 K.
